This application is a request for continued funding of T32 CA79447 at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The Cancer Center is funded by a support grant from the NCI (P30 CA60553). In addition, the Cancer Center has received two SPORE grants [SPORE in Breast Cancer (P50 CA89018) and SPORE in Prostate Cancer (P50 CA90386)] from the NCI. The Clinical Oncology Research Training Program brings together laboratory scientists, clinical investigators and medical fellows to focus on the molecular biology, cell biology, biochemistry and signal transduction pathways of normal and neoplastic cells. This is accomplished through laboratory investigation, organized meetings, journal clubs, seminars and symposia. These activities provide opportunities for sharing the latest scientific results and promoting collaborations. The laboratory preceptors are all NIH funded investigators and they belong to all four basic science programs of the Cancer Center: Viral Oncogenesis; Tumor Invasion, Metastasis and Angiogenesis; Signal Transduction and Cancer and Cancer Genes and Molecular Regulation. The Program has successfully trained 12 fellows (five remain in training, one minority trainee) during the last 3.5 years. Trainees attend the educational activities (laboratory meetings, journal club, seminars, symposia) associated with the Program in addition to their laboratory research. Six out of seven graduates have accepted academic positions. Significant effort is being invested to recruit additional minority students to the Program. Based on our expectation that we will maintain the same candidate pool of highly qualified applicants we request continued funding for four fellow positions per year for a period of five years in the present application. This will enable us to continue focused training in clinical oncology research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA079447-08
Application #
7060957
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1999-01-13
Project End
2009-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
8
Fiscal Year
2006
Total Cost
$232,379
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Gadd, Samantha; Huff, Vicki; Walz, Amy L et al. (2017) A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet 49:1487-1494
Ooms, Ariadne H A G; Gadd, Samantha; Gerhard, Daniela S et al. (2016) Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res 22:5582-5591
Principe, Daniel R; DeCant, Brian; Diaz, Andrew M et al. (2016) PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 7:28218-34
Ozden, Ozkan; Bishehsari, Faraz; Bauer, Jessica et al. (2016) Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer. Sci Rep 6:26273
Zhou, Zheng; Rademaker, Alfred W; Gordon, Leo I et al. (2016) High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw 14:1274-1281
Walz, Amy L; Ooms, Ariadne; Gadd, Samantha et al. (2015) Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:286-97
Zhou, Zheng; Gao, Juehua; Popovic, Relja et al. (2015) Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 56:2895-901
Curi, Dany A; Beauchamp, Elspeth M; Blyth, Gavin T et al. (2015) Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget 6:33206-16
Kumar, Krishan; Raza, Sania S; Knab, Lawrence M et al. (2015) GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep 5:9489
Adekola, Kehinde U A; Dalva Aydemir, Sevim; Ma, Shuo et al. (2015) Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk Lymphoma 56:450-9

Showing the most recent 10 out of 36 publications